What is the purpose of this trial?
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY 1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.
Bayer Healthcare Pharmaceuticals, Inc.
Dates: 04/18/2017 - 08/31/2017
Last Updated: 07/30/2017
Study HIC#: 2000020085